Specifically, we hypothesized that EGFR signaling represents a potential avenue for enhancing NSPC activity in the context of the declining neurogenesis that occurs during normal aging (Eriksson et al., 1998; Curtis et al., 2003; Luo et al., 2006; Shook et al., 2012; Ernst and Frisen, 2015; Daynac et al., 2016) and that is further accelerated in Alzheimer’s disease (AD) (Ziabreva et al., 2006; Hamilton et al., 2010, 2015; Moreno-Jimenez et al., 2019; Scopa et al., 2020). Here, EGFR is linked to Alzheimer disease.